Rectal cancer survivors: study sheds light on hidden side effects
NCT ID NCT07389863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at sexual and gynecological problems that women may face after finishing treatment for rectal cancer. Researchers will survey 15 women in remission about their symptoms using standard questionnaires. The goal is to better understand these long-term effects and identify risk factors, which could help improve support and care for future patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict and manage sexual and gynecological problems after rectal cancer treatment.
- What could go wrong
- This is a small, observational study with only 15 participants, so findings may not apply to all patients. It does not test any new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing treatment for rectal cancer benefit from regular follow-up consultations with the digestive surgeon, allowing for the estimation of the prevalence and characteristics of sexual dysfunctions and gynecological sequelae through questionnaires.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18 to 60 at the time of diagnosis * Having been treated for rectal cancer between 2020 and 2025 * Cancer in remission * Having been sexually active before receiving treatment for their rectal cancer * Having completed the various questionnaires during their treatment Exclusion Criteria: * Inability to complete questionnaires (cognitive impairment, language barrier) * Pregnant women * Women with active cancer and/or undergoing chemotherapy * Women with a history of extensive gynecological surgery * Individuals deprived of their liberty by an administrative or judicial decision, or individuals under legal protection/guardianship or curatorship * Individuals without social security coverage
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal cancer patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Service de Chirurgie Digestive
RECRUITINGRouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a nasal tube replace a temporary ileostomy after rectal cancer surgery?
- Blood test and CT combo may spare rectal cancer patients a second surgery
- Radiation may spare early rectal cancer patients from radical surgery
- New drug cocktail aims to shrink rectal tumors and avoid colostomy
- Vaccinia virus targets rectal tumors in new immunotherapy combo
- New triple therapy aims to wipe out rectal cancer before surgery